Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

Cited by (228)

Items 101–200 of 228

1. Multi‐omic network analysis identified betacellulin as a novel target of omega‐3 fatty acid attenuation of western diet‐induced nonalcoholic steatohepatitis
   Jyothi Padiadpu, Manuel García‐Jaramillo, Nolan K. Newman, Jacob W. Pederson, Richard Rosario Rodrigues, Zhipeng Li, S. P. Singh, Philip M. Monnier, Giorgio Trinchieri, Kevin Brown et al. · 2023 · EMBO Molecular Medicine
2. Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model
   Jesús Funuyet‐Salas, Agustín Martín Rodríguez, María Ángeles Pérez-San-Gregorio, Manuel Romero‐Gómez · 2021 · Journal of Clinical Medicine
3. Targeting Lactylation: From Metabolic Reprogramming to Precision Therapeutics in Liver Diseases
   Qinghai Tan, Mei Liu, Xiang Tao · 2025 · Biomolecules
4. Factors Associated with Liver Fibrosis in Chinese Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
   Yu Luo, Cuiyu Wang, Tian Zhang, Xiaoyu He, Jianan Hao, Andong Shen, Hang Zhao, Shuchun Chen, Luping Ren · 2023 · International Journal of General Medicine
5. Hepatic PTP4A1 ameliorates high-fat diet-induced hepatosteatosis and hyperglycemia by the activation of the CREBH/FGF21 axis
   Byungtae Hwang, Min‐Gi Kwon, Min Ji Cho, Nam-Kyung Lee, Jangwook Lee, Jeong-Woong Lee, Kyoung‐Jin Oh, Kwang‐Hee Bae, Jung Hwan Hwang, Jeong‐Ki Min et al. · 2023 · Theranostics
6. Effects of time restricted feeding combined with Lacto Ovo vegetarian diet on metabolic associated fatty liver disease management: a randomized clinical trial
   Mahshad Shafiee, Amir Sadeghi, Fateme Ghafouri-Taleghani, Maryam Nilghaz, Maryam Ghods, Behnaz Narimani, A. Hekmatdoost, Atoosa Saidpour · 2025 · Scientific Reports
7. Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study
   Feng Gao, Kenneth I. Zheng, Sui‐Dan Chen, Dong Hyeon Lee, Xi-Xi Wu, Xiao-Dong Wang, Giovanni Targher, Christopher D. Byrne, Yong-Ping Chen, Won Kyum Kim et al. · 2021 · Clinical and Translational Gastroenterology
8. Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
   Johannes Bernhard, Lukas Galli, Walter Stefan Speidl, Konstantin Alexander Krychtiuk · 2025 · Current Cardiology Reports
9. Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin
   Thaw Dar Htet, Anastasia Godneva, Zhixin Liu, Eliza Chalmers, Dmitry S. Kolobkov, JENNIFER R. SNAITH, Renee Richens, Krisztina Toth, Mark Danta, Tien‐Ming Hng et al. · 2020 · BMJ Open
10. Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway
    Meng-Yuan Niu, Gengting Dong, Yi Li, Qing Luo, L.-L. Cao, Ximin Wang, Qi-Wen Wang, Yi-Ting Wang, Zhe Zhang, Xi-Wen Zhong et al. · 2024 · World Journal of Gastroenterology
11. The Role of Oxidative Stress and the Potential Therapeutic Benefits of Aronia melanocarpa Supplementation in Obstructive Sleep Apnea Syndrome: A Comprehensive Literature Review
    Alicja Jelska, Agnieszka Polecka, Andrii Zahorodnii, Ewa Olszewska · 2024 · Antioxidants
12. A systems biology approach to study non-alcoholic fatty liver (NAFL) in women with obesity
    Abraham Stijn Meijnikman, Dimitra Lappa, Hilde Herrema, Ömrüm Aydin, Kimberly A. Krautkramer, Valentina Tremaroli, Louise E. Olofsson, Annika Lundqvist, Sjoerd C. Bruin, Yaïr I. Z. Acherman et al. · 2022 · iScience
13. Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity
    Sara De Nucci, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Martina Di Chito, Roberta Rinaldi, Vito Giannuzzi, Raffaele Cozzolongo, Giuseppina Piazzolla, Gianluigi Giannelli et al. · 2022 · Frontiers in Nutrition
14. Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
    Wasitha P. D. W. Thilakarathna, H.P. Vasantha Rupasinghe · 2024 · Molecules
15. Three-Dimensional Dynamic Cell Models for Metabolic Dysfunction-Associated Steatotic Liver Disease Progression
    Huang, Zhengxiang, Li, Lili, Dudley, Kevin, Xiao, Lan, Huang, Gary, Subramaniam, V. Nathan, Chen, Chen, Crawford, Ross, Xiao, Yin · 2025 · BME Frontiers
16. The association between cadmium exposure and the risk of early liver disease: A systematic review and meta-analysis.
    Hualing Zhang, Yue Jing, Lan Guan, Jianlan Luo, Ming Zeng · 2025 · Regulatory toxicology and pharmacology : RTP
17. AAA-ATPase valosin-containing protein binds the transcription factor SREBP1 and promotes its proteolytic activation by rhomboid protease RHBDL4
    Koji Shibuya, Ken Ebihara, Chihiro Ebihara, Nagisa Sawayama, Masayo Isoda, Daisuke Yamamuro, Manabu Takahashi, Shuichi Nagashima, Shun Ishibashi · 2022 · Journal of Biological Chemistry
18. Innate antiviral immunity and immunometabolism in hepatocytes
    Vasile Mihai Sularea, Jamie A. Sugrue, Cliona O’Farrelly · 2022 · Current Opinion in Immunology
19. Nicotine aggravates high-fat diet-induced non-alcoholic fatty liver disease in mice via inhibition of CISD3
    Yi-Feng Wei, Tongtong Pan, Youhong Zhao, Zhiyi Chen, Lina Wu, Xiaowei Wang, Xiaodong Wang, Xiaodong Wang, Dazhi Chen, Yongping Chen · 2024 · International Immunopharmacology
20. Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
    Willy B. Theel, Bianca M. Boxma‐de Klerk, Femme Dirksmeier-Harinck, Elisabeth F. C. van Rossum, Danny A Kanhai, Jan A. Apers, Bas M. van Dalen, Robert Jacobus de Knegt, Bojou J. Neecke, Ellen M. van der Zwan et al. · 2023 · BMJ Open
21. Loss of RAGE prevents chronic intermittent hypoxia-induced nonalcoholic fatty liver disease via blockade of NF-кB pathway
    Haoqu Tan, Jinfang Hu, Wei Zuo, Yun Huang, Jian Cui, Fei Gong, Wei Bai · 2022 · Gene Therapy
22. Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis
    Tymofiy Lutsiv, John N. McGinley, Elizabeth S. Neil, Michelle T. Foster, Henry J. Thompson · 2023 · Nutrients
23. Sex hormone binding globulin (SHBG) as a predictor of liver fibrosis in subjects with nonalcoholic fatty liver disease (NAFLD)
    Abeer Abdel-latif, Ula Mabid Al-Jarhi, Dina Hesham, Mona Khozam, Shaimaa A. Fathy · 2023 · The Egyptian Journal of Internal Medicine
24. Rats with high aerobic capacity display enhanced transcriptional adaptability and upregulation of bile acid metabolism in response to an acute high‐fat diet
    Harrison D. Stierwalt, E. Matthew Morris, Adrianna Maurer, Udayan M. Apte, Kathryn Phillips, Tiangang Li, Grace Margaret-Eleanor Meers, Lauren G. Koch, Steven L. Britton, Greg Graf et al. · 2022 · Physiological Reports
25. Dietary Long-Chain Fatty Acids Accelerate Metabolic Dysfunction in Guinea Pigs with Non-Alcoholic Steatohepatitis
    Kamilla Pedersen, David Højland Ipsen, Josephine Skat‐Rørdam, Jens Lykkesfeldt, Pernille Tveden‐Nyborg · 2023 · Nutrients
26. Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice
    Marcos F. Fondevila, Eva Nóvoa, Uxia Fernandez, Valentina Dorta, Tamara Parracho, Henriette Kreimeyer, Maria García-Vence, María del Pilar Chantada‐Vázquez, Susana B. Bravo, Begoña Porteiro et al. · 2024 · Molecular Metabolism
27. Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus
    Eirini Siafi, Ioannis Andrikou, D. Konstantinidis, Niki Kakouri, Panagiotis Iliakis, John Koskinas, Emmanouil Koullias, Eleftherios Thireos, Dimitris Tousoulis, Costas Thomopoulos et al. · 2021 · Journal of Hypertension
28. 5-Aminolevulinic Acid Attenuates Glucose-Regulated Protein 78 Expression and Hepatocyte Lipoapoptosis via Heme Oxygenase-1 Induction
    Takaaki Hashimoto, Takaaki Sugihara, Tsutomu Kanda, Tomoaki Takata, Hajime Isomoto · 2021 · International Journal of Molecular Sciences
29. Herbal medicine as a potential treatment for non-alcoholic fatty liver disease
    Wenyi Nie, Ye Yang, Hongxuan Tong, Jingqing Hu · 2025 · World Journal of Gastroenterology
30. The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease
    Keerthi Thallapureddy, David Twitchell, Kristen Ott, Lisa D. Pedicone, Chioma Owo, Nina Kumar, Jonathan Gelfond, Nagasri Shankar, Martin W. Goros, Daisy Kwok et al. · 2025 · Medicine
31. Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis
    Alison-Michelle Naujack, Christin Krause, Jan H. Britsemmer, Natalie Taege, Jens Mittag, Henriette Kirchner · 2024 · European Thyroid Journal
32. Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease
    Plator Memaj, Zayd Ouzerara, François R. Jornayvaz · 2023 · International Journal of Molecular Sciences
33. Vanadium Complexes with Thioanilide Derivatives of Amino Acids: Inhibition of Human Phosphatases and Specificity in Various Cell Models of Metabolic Disturbances
    Grzegorz Kazek, Monika Głuch‐Lutwin, Barbara Mordyl, Elżbieta Menaszek, Monika Kubacka, Anna Jurowska, Dariusz Cież, Bartosz Trzewik, Janusz Szklarzewicz, Monika A. Papiez · 2024 · Pharmaceuticals
34. Fighting liver fat
    David Koeckerling, Jeremy Tomlinson, Jeremy Cobbold · 2020 · Endocrine Connections
35. Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
    Adriaan Georgius Holleboom, Sven Francque, Kenneth J. Cusi, Cyrielle Caussy · 2025 · Metabolism Open
36. Identification of potential metabolic biomarkers and immune cell infiltration for metabolic associated steatohepatitis by bioinformatics analysis and machine learning
    Haoran Xie, Jun-Jun Wang, Qiuyan Zhao · 2025 · Scientific Reports
37. Exosome-associated miRNA-99a-5p targeting BMPR2 promotes hepatocyte apoptosis during the process of hepatic fibrosis
    Feng Li, Tengfei Yan, Shunlan Wang, Xiaohong Wen · 2023 · Clinical and Experimental Medicine
38. Repeated detection of non‐alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults
    Jin Hwa Kim, Young Sang Lyu, Mee Kyoung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon · 2023 · Diabetes Obesity and Metabolism
39. Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population
    Jingwei Zhang, Shijie Ma, Wei Zhou, Jing Feng, Yuwei Kang, Wei Cai Yang, Heping Zhang, Fei Deng · 2023 · Toxicology and Applied Pharmacology
40. Promotion of nonalcoholic steatohepatitis by RNA N6-methyladenosine reader IGF2BP2 in mice
    Bing Zhou, Yunchen Luo, Nana Ji, Fei Mao, Liping Xiang, Hua Bian, Ming‐Hua Zheng, Cheng Hu, Yao Li, Yan Lü · 2022 · Life Metabolism
41. Age-Related Dietary Habits and Blood Biochemical Parameters in Patients with and without Steatosis—MICOL Cohort
    Rossella Donghia, Pasqua Letizia Pesole, Antonino Castellaneta, Sergio Coletta, Francesco Squeo, Caterina Bonfiglio, Giovanni De Pergola, Roberta Rinaldi, Sara De Nucci, Gianluigi Giannelli et al. · 2023 · Nutrients
42. The pathogenesis of metabolic dysfunction-associated steatotic liver disease and nucleoside reverse transcriptase inhibitors (NRTIs) -based HIV-antiretroviral regimens: A comprehensive narrative review
    Marilize Horn, Nontobeko Myllet Gumede, Mlindeli Wilkinson Gamede · 2025 · Biomedicine & Pharmacotherapy
43. IRW improves diet-induced non-alcoholic fatty liver disease by reducing steatosis associated with increased capacity for oxidative phosphorylation
    Stepheny C. de Campos Zani, Emily Vanden Berg, Xu Jiang, Alexandra Knox, Evan Ackroyd, Aaron Getachew, Jianping Wu, Catherine B. Chan · 2023 · Journal of Functional Foods
44. The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease
    Na Ao, Jian Du, Shi Jin, Linna Suo, Jing Yang · 2024 · Diabetes Obesity and Metabolism
45. Aggravation of hepatic lipidosis in red-footed tortoise Chelonoidis carbonaria with age is associated with alterations in liver mitochondria
    Marina R. Sartori, Claudia D.C. Navarro, Roger Frigerio Castilho, Aníbal Eugênio Vercesi · 2022 · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology
46. Improvement of Metabolic and Histological Changes of Adiposity in Rats by Synthetic Oleoyl Chalcones
    Azza A. M. AlKhathami, Hosam A. Saad, Fareed A. Fareed, Eman Salah El‐Shafey, Eslam Samy Elsherbiny, Mamdouh El-Nahas, Mohamed R. E. Aly · 2023 · Chemistry & Biodiversity
47. An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences
    Monika Bhardwaj, Papiya Mitra Mazumder · 2025 · Molecular Biology Reports
48. Association of platelet to albumin ratio with metabolic dysfunction-associated steatotic liver disease based on the National Health and Nutrition Survey 2017–2018
    Jiao Xie, Qingliu He, David P. Fisher, Khrystyna Pronyuk, Erkin Isakovich Musabaev, Lei Zhao · 2025 · Scientific Reports
49. An Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH)
    Santosh Hajare, Varadaraj Gokak, Sandesha Ghorpade, Amar Patil, Arvind Jadhav · 2019 · International Journal of Contemporary Medical Research [IJCMR]
50. Chemical, Microscopic and XRD Studies on Makerwal Coal
    Shafqat Nawaz, Muhammad Arif Butt, Naseer Sheikh, M. Hassan · 2010 · Journal of Faculty of Engineering and Technology
51. MASLD and the cardiovascular-kidney-liver-metabolic syndrome
    Angeliki M. Angelidi, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P. Mikhailidis, George Jacob, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
52. HA-20 prevents hepatocyte steatosis in metabolic-associated fatty liver disease via regulating Ca2+ relative signalling pathways
    Jie Wang, Ming-Ming Du, Yun Du, Jian‐Xin Li · 2022 · European Journal of Pharmacology
53. The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease
    Yuan Dong, Yuejie Zhang, Yingmei Feng, Wei An · 2022 · Frontiers in Pharmacology
54. Glucagon increases plasma levels of cyclic AMP responses in mice and humans, and this may be independent of MASLD
    Josephine Reiche, Alexander Jakobsen, Sasha A. S. Kjeldsen, Christine Bruun Rasmussen, Lise Lotte Gluud, Michael M. Richter, Marie Winther‐Sørensen, Nicolai J. Wewer Albrechtsen · 2025 · American Journal of Physiology-Endocrinology and Metabolism
55. A Current Approach to Non-Alcoholic Steatohepatitis in Type 2 Diabetes Mellitus Patients
    Sorina Ionelia Stan, Teodora Biciusca, Viorel Biciuşcă, Ramona Cioboată, Adina Mitrea, Diana Clenciu, Alice Elena Ghenea, Suzana Dănoiu · 2023 · Gastroenterology Insights
56. Development and Validation of a Risk Prediction Model for NAFLD: A Study Based on a Physical Examination Population
    Chun-Mei Yang, Tingwan Du, Yueying Zhao, Youhui Qian, Jia Tang, Xiaohong Li, Ling Ma · 2024 · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
57. Therapeutic mechanisms of ellagic acid for inflammation and related conditions
    Chenye Zhang · 2023 · International Conference on Modern Medicine and Global Health (ICMMGH)
58. Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target
    Sorina Ionelia Stan, Viorel Biciuşcă, Diana Clenciu, Adina Mitrea, Mihail Virgil Boldeanu, Patricia Durand, Suzana Dănoiu · 2023 · Medicine and Pharmacy Reports
59. Association of physical activity and sports participation with insulin resistance and non‐alcoholic fatty liver disease in people with type 1 diabetes
    M. de Vries, Jan Westerink, Karin A. H. Kaasjager, Harold W. de Valk, the UCC‐SMART Study Group · 2024 · Diabetic Medicine
60. Selenium Nanoparticles Decorated With Stevioside Potentially Attenuate Fructose Palmitate Induced Lipid Accumulation in HepG2 Cells
    Shuai Li, Hui Yang, Wenjun Zhou, Ruoting Wang, Likang Li, Changfa Zhang, Jingyi Zhang, Yingxin Liu, Zhi Huang, Guowei Li · 2025 · Mediators of Inflammation
61. Ameliorating effects of melatonin on high-fat diet induced non-alcoholic fatty liver diseases and their associated pathologies: A comprehensive review
    Songita Ghosh, Razia Khatoon, Swaimanti Sarkar, Debasish Bandyopadhyay · 2023 · Melatonin Research
62. Serum HGF ,PCIII and PLT are Noninvasive Markers for the diagnosis of nonalcoholic fatty liver disease
    Xiuqin An, Jinchun Liu, Xiaojuan Zheng, Zhangfeng Dou, Yue Li, Yuhong Suo, Ya Nan, Meiqing Sun, Zhong Yuan Tian, Lijun Xu · 2019
63. Advances in Probiotics for Health and Nutrition
    Vasudeo Zambare, Mohd Fadhil Md. Din, Puja Gupta, Bhupendra Gopalbhai Prajapati · 2023 · IntechOpen eBooks
64. Bioavailable human metabolites from TOTUM-448 (plant-based formulation) maintain liver cell functionality in a hyperlipidic context that drives MASLD onset
    Fabien Wauquier, Vivien Chavanelle, Annie Bouchard‐Mercier, Line Boutin-Wittrant, Yolanda F. Otero, Stéphanie Krisa, Josep Valls, Florian Le Joubioux, Bruno Pereira, Véronique Roux et al. · 2025 · Scientific Reports
65. Resumen ejecutivo: Enfermedad por hígado graso no alcohólico en sujetos con diabetes mellitus tipo 2: Postura conjunta de la Asociación Chilena de Hepatología (ACHHEP) y la Sociedad Chilena de Diabetología (SOCHIDIAB)
    Juan Pablo Arab, Lorena Castro, PATRICIA C. GOMEZ, Paulina Vignolo, Marco A. Arrese, Francisco Barrera M., Fabiola Castro, Luis Antonio Díaz, Anibal Donoso, Karina Elgueta et al. · 2021 · Revista médica de Chile
66. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver ® ) Diagnoses
    Èlia Navarro‐Masip, Núria Mestres Petit, Blanca Salinas‐Roca, Fernando Herrerías, Felip Vilardell, Mari Cruz de la Fuente, Judit Pallarés, Maite Santamaría, Marta Zorzano-Martínez, Enric Sánchez et al. · 2024 · Obesity Facts
67. Discovery of Cell-Permeable Allosteric Inhibitors of Liver Pyruvate Kinase: Design and Synthesis of Sulfone-Based Urolithins
    Shazia Iqbal, Md. Zahidul Islam, Sajda Ashraf, Woonghee Kim, Amal A. AL-Sharabi, Mehmet Özcan, Essam Hamied Ahmed HANASHALSHAHABY, Cheng Zhang, Mathias Uhlén, Jan Borén et al. · 2024 · International Journal of Molecular Sciences
68. The GIRO Guideline: a key tool to approach the obesity challenge and its impact on digestive health
    Aitor Orive, Serafín Caseiro-González, Irene Moraleja Yudego · 2025 · Revista Española de Enfermedades Digestivas
69. The Unexpected Detection of Esophageal Varices Caused by Liver Cirrhosis in a 47-Year-Old Man Treated with a Growth Hormone in Childhood
    Osamu Arisaka, Satomi Koyama, George Imataka, Junko Naganuma, Takahiro Arisaka, Sei Akatsuka · 2024 · Diseases
70. Bioinformatic Analysis for Exploring Target Genes and Molecular Mechanisms of Cadmium‐Induced Nonalcoholic Fatty Liver Disease and Targeted Drug Prediction
    Le Zhang, Rui Wang, Qian Xue, Yongjie Wang, Jiayunzhu Xu, Chaofan Wang, Xin Fang, Shidi Gao, Haiying Zhang, Guo Li · 2025 · Journal of Applied Toxicology
71. Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management
    Joonpyo Lee, Mi‐Seung Shin · 2025 · Cardiovascular Prevention and Pharmacotherapy
72. Pistacia atlantica can improve oxidative status in patients with metabolic dysfunction-associated fatty liver disease
    Roghayeh Mostafai, Seyed Mostafa Nachvak, Amir Saber, Nazanin Jalilian, Behzad Mahaki, Mohammad Gharib Salehi, Leila Behbood, Zahra Ghorbani, Somayeh Rahimi · 2025 · Scientific Reports
73. Ultrafine garlic powder alleviates non-alcoholic steatohepatitis by inhibiting hepatocyte ferroptosis and modulating ERK-dependent oxidative stress
    Junhui Yu, Ningning Shao, Jianming Yang, Long Yang, Kaiwen Hong, Yuzhu Chen, Xiaoming Zhao, Hongzhi Yu, Tao Zhang, Jinrui Dong · 2025 · Frontiers in Pharmacology
74. Impact of gender and age on the histologic severity of metabolic syndrome associated steatohepatitis
    Eesha K. Acharya, Robert Lam, Joseph K. Lim, Yanhong Deng, Dhanpat Jain · 2025 · Human Pathology
75. Effectiveness of nutrition education program and omega-3 supplementation on body weight, liver enzyme, lipid profile among non-alcoholic fatty liver disease patients
    Dilkhosh Shamal Ramadhan, Ibrahim Hasan Mustafa · 2026 · BMC Nutrition
76. Review on the Role of Fructose in Non-Alcoholic Fatty Liver Diseases
    Isaac John Umaru, Okoli Chikodiri Emmanuel · 2022 · International Journal of Scientific and Management Research
77. An integrative approach to assessing effects of a short-term Western diet on gene expression in rat liver
    Jaclyn E. Welles, Holly A. Lacko, Yuka Imamura Kawasawa, Michael Don Dennis, Leonard S. Jefferson, Scot R. Kimball · 2022 · Frontiers in Endocrinology
78. Non-alcoholic Fatty Liver Disease
    David Koeckerling, Thomas Marjot, Jeremy Cobbold · 2022 · In clinical practice
79. How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting
    Pegah Golabi, Dipam Shah, Zobair M. Younossi · 2023 · Seminars in Liver Disease
80. Manifestations of Liver Impairment and the Effects of MH-76, a Non-Quinazoline α1-Adrenoceptor Antagonist, and Prazosin on Liver Tissue in Fructose-Induced Metabolic Syndrome
    Monika Kubacka, Barbara Nowak, Monika Zadrożna, Małgorzata Szafarz, Gniewomir Latacz, Henryk Marona, Jacek Sapa, Szczepan Mogilski, Marek Bednarski, Magdalena Kotańska · 2023 · Metabolites
81. Identification of biomarkers associated with immune-propionate metabolism in nonalcoholic fatty liver disease
    Shuye Qu, Hui Fang Huang, Yan Diao, Bowei Liu, Baozhu Tang, Shijiao Huo, Lei Yu, Xiuchen Xuan, Wenling Mou, Ping Liu et al. · 2023 · Cellular and Molecular Biology
82. In Vitro to In Vivo Scalars for Drug Clearance in Nonalcoholic Fatty Liver and Steatohepatitis
    Teresa Sierra, B. Achour · 2024 · Drug Metabolism And Disposition
83. Nonalcoholic fatty liver disease associated with obesity and type 2 diabetes and gut dysbiosis
    T. М. Bentsa · 2024 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
84. PNPLA3 rs738409 polymorphism in Patients with Type 2 Diabetes and Concomitant Liver Pathology in Yakutia
    Куртанов Харитон Алексеевич, Nadezhda Ivanovna Pavlova, Aleksandra Diakonova, Liubov A. Sydykova, Sardana V. Markova, Додохов Владимир Владимирович · 2020 · International Journal of Biomedicine
85. Diminution of Liver Aminotransferase Enzymes Levels in Nonalcoholic Fatty Liver Disease by Silymarin: A Case Report
    Ali Azargoonjahromi · 2022 · Research Square
86. Editorial: can urine‐based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply
    Ahmad Moolla, Jeremy Tomlinson · 2020 · Alimentary Pharmacology & Therapeutics
87. What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?
    Javier Escalada · 2020 · Revista Española de Enfermedades Digestivas
88. Non-alcoholic fatty liver disease in pregnancy
    Charlotte S Benson, Jeremy Cobbold, Charlotte Frise · 2021 · Obstetric Medicine
89. Mock examination
    Thomas Marjot · 2021
90. Integrated 16S rRNA and metabolomics investigation of the hepatoprotective effects of Ixeris chinensis on high-fat diet-induced nonalcoholic fatty liver in mice
    Wenjie Jin, Minghai Fu · 2022 · Research Square
91. E-Manuscript Article Summaries
    Current Oncology Editorial Office · 2011 · Current Oncology
92. Frequency of Fatty Liver Changes on Ultrasound Abdomen in Non Diabetic Young Patients Having Chronic Right Hypochondrium Pain
    Syed Anees Ahmed Gardezi, Najmusaqib Khan Niazi, Syed Haider Tirmizi, Iffat Rafique, Rabia Sadiq, Muneeb U. Rehman, Talha Laique · 2022 · Pakistan Journal of Medical and Health Sciences
93. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China
    Qiling Liu, Gang Zhao, Qian Li, Weiyun Wu, Yan Zhang, Hua Bian · 2022 · Research Square
94. КОМОРБІДНА ПАТОЛОГІЯ ПЕЧІНКИ У ПАЦІЄНТІВ, ЯКІ ЖИВУТЬ З ОЖИРІННЯМ
    Г. В. Корнован, V. I. Synenko, Лариса Колотвіна, Яна Бажора, Дарʼя Лагода, Вероніка Назарян, Ганна Амірова, Олена Паслар · 2022 · ГРААЛЬ НАУКИ
95. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China
    Qiling Liu, Gang Zhao, Qian Li, Weiyun Wu, Yan Zhang, Hua Bian · 2022 · Research Square
96. IRW prevents diet-induced non-alcoholic fatty liver disease by preserving mitochondrial content and enhancing hepatic fatty acid oxidation capacity
    Stepheny C. de Campos Zani, Emily Vanden Berg, Xu Jiang, Alexandra Knox, Evan Ackroyd, Aaron Getachew, Jianping Wu, Catherine B. Chan · 2023 · Research Square
97. Kegiatan Pengabdian Masyarakat dalam Rangka Peningkatan Pemahaman Masyarakat Tentang Penyakit Perlemakan Hati dan Deteksi Dini Penyakit Liver
    Shirly Gunawan, Alicia Sarijuwita, Vini Claudya Agustine Rajagukguk, Yohanes Firmansyah · 2023 · Jurnal Pengabdian Ilmu Kesehatan
98. EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON THE COURSE OF DIABETIC POLYNEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    A.Ya. Sabovchyk · 2023 · Wiadomości Lekarskie
99. Nonalcoholic Fatty Liver Disease, Procalcitonin, and Gut Microbiota: Players in the Same Team
    Doina Georgescu, Ana Lascu, Ioana Ioniță, Oana Ancusa, Mihai Ionita, Ciprian Ilie Rosca, Despina Călămar-Popovici, Daniel Lighezan · 2023 · IntechOpen eBooks
100. Gan nhiễm mỡ liên quan chuyển hóa và xơ vữa động mạch cảnh
     Bảo Vũ Quốc · 2023 · Pham Ngoc Thach Journal of Medicine and Pharmacy